Ophthalmic composition for promoting tear secretion

By using 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octane -1-yl]-3-oxopropionitrile (digotinib) as an ophthalmic composition solves the problem of insufficient tear secretion in the prior art, and achieves improvement of keraconjunctival epithelial disease and relieve symptoms.

CN118903144APending Publication Date: 2024-11-08ROHTO PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410802175.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2019-12-27
Filing Date
2020-08-06
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The prior art is difficult to effectively promote tear secretion, especially in exogenous diseases caused by keratoconjunctival epithelial diseases such as dry eye disease and contact lenses, resulting in symptoms such as tears, foreign body sensation, eye pain.

Method used

3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octane- 1-yl]-3-oxopropionitrile (digotinib) or a salt thereof is administered as an ophthalmic composition in the form of eye drops to promote tear secretion and improve keratoconjunctival epithelial disease.

Benefits of technology

It significantly promotes tear secretion and improves keratoconjunctival epithelial diseases, especially in dry eye disease and other endogenous and exogenous keratoconjunctival epithelial diseases, and effectively relieves symptoms and improves the healthy state of the corneal epithelium.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903144A_ABST
    Figure CN118903144A_ABST
Patent Text Reader

Abstract

The present invention relates to an ophthalmic composition for promoting tear secretion, which contains 3-[(3S, 4R)-3-methyl-6-(7H-pyrrolo [2, 3-d] pyrimidin-4-yl)-1, 6-diazaspiro [3.4] octane-1-yl]-3-oxopropionitrile or a salt thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention is a divisional application of the Chinese patent application with application number 202080055566.8, application date August 6, 2020, and invention name “Ophthalmic composition for promoting tear secretion”. This application claims the priority of Japanese Patent Application No. 2019-145670 filed in Japan on August 7, 2019 and Japanese Patent Application No. 2019-239605 filed in Japan on December 27, 2019. Technical Field

[0002] The present invention relates to an ophthalmic composition for promoting tear secretion. Background Art

[0003] Corneal and conjunctival epithelial diseases are caused by endogenous diseases such as dry eyes or exogenous diseases caused by wearing contact lenses, and are diseases that present symptoms such as tearing, foreign body sensation, eye pain, and congestion. As a therapeutic agent for corneal and conjunctival epithelial diseases, eye drops containing sodium hyaluronate are already sold on the market. Sodium hyaluronate has the effect of promoting corneal epithelial stretching and retaining moisture. In addition, it has been reported that in a rat dry eye model, diquafosol sodium, as a dry eye therapeutic agent, promotes tear secretion and improves corneal epithelial diseases (e.g., non-patent document 1).

[0004] On the other hand, Janus kinase (JAK) is a non-receptor tyrosine kinase that plays an important role in the transmission of immune activation signals in cells, and drugs having Janus kinase inhibitory activity are expected to improve autoimmune diseases or allergic diseases by inhibiting excessive activation of immune responses. Here, as one of the compounds having Janus kinase inhibitory activity, 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropionitrile (generic name: delgocitinib) is known (for example, Patent Document 1).

[0005] Prior art literature

[0006] Patent Literature

[0007] Patent Document 1: International Publication No. 2017 / 006968

[0008] Non-patent literature

[0009] Non-patent document 1: Diquas Eye Drops 3% Accessories (revised in November 2017) Summary of the invention

[0010] Technical Problems to be Solved by the Invention

[0011] The object of the present invention is to provide a novel ophthalmic composition capable of promoting tear secretion.

[0012] Technical means to solve technical problems

[0013] The inventors of the present application conducted intensive research to solve the above technical problems and found that 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropionitrile can promote tear secretion and improve corneal epithelial diseases. The present invention provides the following inventions based on this finding. [1]

[0015] An ophthalmic composition for promoting tear secretion, comprising 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropionitrile or a salt thereof. [2]

[0017] The ophthalmic composition according to [1], which is used for improving corneal and conjunctival epithelial diseases. [3]

[0019] The ophthalmic composition according to [1], which is used for improving dry eye syndrome. [4]

[0021] An ophthalmic composition for improving corneal epithelial diseases, comprising 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropionitrile or a salt thereof. [5]

[0023] The ophthalmic composition according to [2] or [4], wherein the corneal and conjunctival epithelial disease is caused by dry eye. [6]

[0025] The ophthalmic composition according to any one of [1] to [5], wherein the content of 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropionitrile or its salt is 0.01% by mass to 1% by mass based on the total amount of the ophthalmic composition. [7]

[0027] The ophthalmic composition according to any one of [1] to [6], which is an eye drop. [8]

[0029] A method for promoting tear secretion, comprising administering an ophthalmic composition containing 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropionitrile or a salt thereof, or both, to a subject. [9]

[0031] A method for improving corneal epithelial diseases, comprising administering an ophthalmic composition containing 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropionitrile or a salt thereof, or both thereof, to a subject.

[10]

[0033] The method according to [9], wherein the corneal and conjunctival epithelial disease is caused by dry eye.

[11]

[0035] Use of 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropionitrile or a salt thereof in the preparation of an ophthalmic composition for promoting tear secretion.

[12]

[0037] Use of 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropionitrile or a salt thereof in the preparation of an ophthalmic composition for improving corneal and conjunctival epithelial diseases.

[13]

[0039] The use according to

[12] , wherein the corneal and conjunctival epithelial disease is caused by dry eye.

[14]

[0041] Disclosed is 3-[(3S, 4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropionitrile or a salt thereof for promoting tear secretion.

[15]

[0043] Disclosed is 3-[(3S, 4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropionitrile or a salt thereof for improving corneal and conjunctival epithelial diseases.

[16]

[0045] The compound or a salt thereof according to

[15] , wherein the corneal and conjunctival epithelial disease is caused by dry eye.

[0046] Effects of the Invention

[0047] According to the present invention, an ophthalmic composition capable of promoting tear secretion can be provided. BRIEF DESCRIPTION OF THE DRAWINGS

[0048] Figure 1 This is a graph showing the tear secretion promoting effect obtained by single eye drop administration of digotinib using normal rabbits in Test Example 1.

[0049] Figure 2 This is a graph showing the tear secretion promoting effect obtained by single eye drop administration of digotinib using normal mice in Test Example 2.

[0050] Figure 3 (A) is a graph showing the tear secretion promoting effect of a single eye drop administration of digotinib using normal rats in Experimental Example 3; (B) is a graph showing the tear secretion promoting effect of a single eye drop administration of digotinib using lacrimal gland removed rats in Experimental Example 3.

[0051] Figure 4 This is a graph showing the tear volume increasing effect obtained by repeated eye drop administration of digotinib using lacrimal gland removal rats in Test Example 4.

[0052] Figure 5 This is a graph showing the improvement effect of corneal and conjunctival epithelial diseases obtained by repeated eye drop administration of digotinib using lacrimal gland enucleated rats in Test Example 5. DETAILED DESCRIPTION

[0053] Hereinafter, embodiments for implementing the present invention will be described in detail, but the present invention is not limited to the following embodiments.

[0054] The ophthalmic composition of the present embodiment contains 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropionitrile or a salt thereof.

[0055] 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropionitrile (common name: digotinib) is a compound represented by the following formula (hereinafter, this compound is also referred to as "digotinib"). Digotinib or a salt thereof can be prepared by the method described in International Publication No. 2017 / 006968 and International Publication No. 2018 / 117151, for example.

[0056] [Chemical formula 1]

[0057]

[0058] The salt of digotinib is not particularly limited as long as it is a salt that is medically, pharmacologically (pharmaceutically) or physiologically acceptable. Specifically, such salts include salts with inorganic acids, salts with organic acids, salts with inorganic bases, salts with organic bases, salts with acidic amino acids, salts with basic amino acids, and the like.

[0059] Examples of salts with inorganic acids include salts with hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Examples of salts with organic acids include salts with acetic acid, succinic acid, fumaric acid, maleic acid, tartaric acid, citric acid, lactic acid, stearic acid, benzoic acid, mesylic acid, ethanesulfonic acid, p-toluenesulfonic acid, and the like. Examples of salts with inorganic bases include alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts; aluminum salts; ammonium salts, and the like. Examples of salts with organic bases include salts with diethylamine, diethanolamine, meglumine, N,N-dibenzylethylenediamine, and the like. Examples of salts with acidic amino acids include salts with aspartic acid, glutamic acid, and the like. Examples of salts with basic amino acids include salts with arginine, lysine, ornithine, and the like.

[0060] Digotinib or its salt exerts an effect of promoting tear secretion. Therefore, as one embodiment of the present invention, an ophthalmic composition for promoting tear secretion containing digotinib or its salt is provided. In addition, the promotion of tear secretion is considered to be a major cause of improvement in corneal and conjunctival epithelial diseases. Therefore, as one embodiment of the present invention, an ophthalmic composition for improving corneal and conjunctival epithelial diseases containing digotinib or its salt is provided. In addition, there has been no report so far on promoting tear secretion by inhibiting Janus kinase.

[0061] The ophthalmic composition of this embodiment can be used for corneal epithelial diseases caused by endogenous diseases such as dry eye (Sjogren's syndrome), Sjögren's syndrome, and Stevens-Johnson syndrome; it can also be used for corneal epithelial diseases caused by exogenous diseases such as postoperative, drug-induced, trauma, and wearing contact lenses. Among them, the ophthalmic composition of this embodiment promotes tear secretion by containing digotinib or its salt, so it is preferably used to improve corneal epithelial diseases caused by endogenous factors, and more preferably used to improve corneal epithelial diseases caused by dry eye. Dry eye that causes corneal epithelial diseases can be dry eye caused by autoimmune diseases such as Sjögren's syndrome, or dry eye caused by factors other than autoimmune diseases.

[0062] Furthermore, the ophthalmic composition of this embodiment can also be used to improve dry eye disease because it contains digotinib or a salt thereof to promote tear secretion. Dry eye disease may be dry eye disease caused by autoimmune diseases such as Sjögren's syndrome or dry eye disease caused by factors other than autoimmune diseases.

[0063] The content of digotinib or its salt in the ophthalmic composition of the present embodiment is not particularly limited, and can be appropriately set according to the types and contents of other blending ingredients, the formulation form, etc. As the content of the component (A), from the perspective of more significantly exerting the effect of the present invention, for example, based on the total amount of the ophthalmic composition of the present embodiment, the total content of digotinib or its salt can be 0.001% by mass to 10% by mass, 0.001% by mass to 5% by mass, 0.003% by mass to 3% by mass, 0.005% by mass to 1% by mass, 0.01% by mass to 0.5% by mass, 0.015% by mass to 0.4% by mass, 0.02% by mass to 0.3% by mass, or 0.03% by mass to 0.3% by mass.

[0064] The ophthalmic composition of the present embodiment may contain appropriate amounts of various additives by appropriately selecting them according to the formulation form or using them alone or in combination of more than one kind according to a conventional method, as long as the effects of the present invention are not impaired.

[0065] The pH of the ophthalmic composition of the present embodiment is not particularly limited as long as it is within a pharmaceutically, pharmacologically (pharmaceutically) or physiologically acceptable range.

[0066] The ophthalmic composition of the present embodiment can be prepared, for example, by adding and mixing digotinib or its salt and other components as required in a desired content. Specifically, for example, it can be prepared by dissolving or suspending the above components in purified water and sterilizing them by filtration sterilization or the like.

[0067] The ophthalmic composition of the present embodiment can be in various dosage forms depending on the purpose, and examples thereof include liquid preparations, gel preparations, semisolid preparations (ointments, etc.), etc. Among them, liquid preparations are preferred, and aqueous liquid preparations are more preferred.

[0068] The ophthalmic composition of the present embodiment can be used as, for example, eye drops (also referred to as eye drops or eye drops; and eye drops include artificial tears, eye drops that can be instilled while wearing contact lenses).

[0069] When the ophthalmic composition of the present embodiment is an eye drop, its usage and dosage are not particularly limited as long as the effect is exerted and side effects are few.

[0070] As one embodiment of the present invention, a method for promoting tear secretion is provided, wherein an ophthalmic composition containing digotinib or a salt thereof, or both, is administered to a subject. In addition, as one embodiment of the present invention, a method for improving corneal and conjunctival epithelial diseases is provided, wherein an ophthalmic composition containing digotinib or a salt thereof, or both, is administered to a subject.

[0071] As one embodiment of the present invention, there is provided use of digotinib or a salt thereof in preparing an ophthalmic composition for promoting tear secretion. In addition, as one embodiment of the present invention, there is provided use of digotinib or a salt thereof in preparing an ophthalmic composition for ameliorating corneal and conjunctival epithelial diseases.

[0072] As one embodiment of the present invention, digotinib or a salt thereof for promoting tear secretion is provided. In addition, as one embodiment of the present invention, digotinib or a salt thereof for improving corneal and conjunctival epithelial diseases is provided.

[0073] Example

[0074] The present invention is specifically described below based on test examples, but the present invention is not limited thereto. In the following test examples, unless otherwise specified, the unit "%" of the content means "w / v%", which is synonymous with "g / 100 mL".

[0075] [Test Example 1: Tear secretion promoting effect of single eye drop administration of digotinib using normal rabbits]

[0076] Normal rabbits were used to evaluate the tear secretion promoting effect of digotinib.

[0077] Digotinib was dissolved in PBS (Phosphate buffered saline) (Kohjin-Bio Co., Ltd.) and stirred to prepare a 0.05% digotinib solution. After placing a male Japanese white rabbit (Oriental Yeast Co., Ltd.) in a restraining tube, PBS or 0.05% digotinib solution was dripped into the eye at a dose of 50 μL / eye. After 15 minutes, a Schirmer test paper was inserted into the conjunctival sac on the outer corner of the eye. After 1 minute, the test paper was pulled out and the length of the wet part of the test paper was measured. The measured value was used as the tear volume. The results are shown in Figure 1 .

[0078] like Figure 1 As shown, the tear volume was significantly increased in the digotinib solution group compared with the PBS group (t test).

[0079] [Test Example 2: Tear secretion promoting effect of single eye drop administration of digotinib using normal mice]

[0080] The tear secretion promoting effect of digotinib was evaluated using normal mice.

[0081] Digotinib was dissolved in PBS (Kohjin-Bio Co., Ltd.) and stirred to prepare digotinib solutions of various concentrations (0.0125%, 0.05% and 0.2%). Female C57BL / 6J mice (Japan SLC, Inc.) were restrained, and PBS or digotinib solutions of various concentrations were dripped into the eyes at a dose of 3 μL / eye. After 15 minutes, a phenol red cotton thread (ZONE-QUICK, AYUMI Pharmaceutical Corporation) was inserted into the conjunctival sac on the outer corner of the eye. After 15 seconds, the phenol red cotton thread was pulled out, and the length of the wetted part of the phenol red cotton thread was measured, and the measured value was used as the tear volume. The results are shown in Figure 2 middle.

[0082] like Figure 2 As shown, the tear volume increased in the digotinib solution groups at each concentration compared with the PBS group, and a significant increase was observed in the 0.05% and 0.2% groups in particular (Dunnett's test).

[0083] [Test Example 3: Tear secretion promoting effect of single eye drop administration of digotinib using normal rats and lacrimal gland removed rats]

[0084] The tear secretion promoting effect of digotinib was evaluated using normal rats and lacrimal gland removed rats.

[0085] A 0.05% digotinib solution (a solution obtained by mixing digotinib as an active ingredient and sodium chloride, potassium chloride, sodium hydroxide, boric acid, and chlorhexidine gluconate as additives in purified water and dissolving and stirring) was prepared as a test substance. As a control substance, a 3% pilocarpine solution was prepared by dissolving pilocarpine hydrochloride (Tokyo Chemical Industry Co., Ltd.) in physiological saline (Otsuka Normal Saline, Otsuka Pharmaceutical Factory, Inc.) and stirring.

[0086] Physiological saline, Diquas eye drops 3% (Santen Pharmaceutical Co., Ltd.), 3% pilocarpine solution or 0.05% digotinib solution were dripped into the eyes of normal male Sprague-Dawley (SD) rats (Japan SLC, Inc.) and SD rats whose main and accessory lacrimal glands had been removed one week ago at a dosage of 5 μL / eye. After 10 minutes, sodium pentobarbital (Kyoritsu Seiyaku Corporation) was used for anesthesia introduction, and after further 5 minutes, a Schirmer test paper was inserted into the conjunctival sac on the outer corner of the eye. After 1 minute, the test paper was pulled out, and the length of the wet part of the test paper was measured, and the measured value was used as the tear volume. The results are shown in Figure 3 .

[0087] like Figure 3 As shown, in normal rats, the tear volume increased significantly in the Diquas eye drops 3% group, the 3% pilocarpine solution group, and the 0.05% digotinib solution group compared with the saline group (Mann-Whitney U test). On the other hand, in lacrimal gland removal rats, the tear volume increased significantly only in the Diquas eye drops 3% group and the 0.05% digotinib solution group compared with the saline group (Mann-Whitney U test).

[0088] [Test Example 4: Tear volume increasing effect obtained by repeated eye drop administration of digotinib using lacrimal gland enucleated rats]

[0089] The tear volume-increasing effect of digotinib was evaluated using lacrimal gland-removed rats, which can be used as a dry eye model.

[0090] Digotinib was dissolved in PBS (Kohjin-Bio Co., Ltd.) and stirred to prepare digotinib solutions of various concentrations (0.0125%, 0.05%, and 0.2%).

[0091] PBS or digotinib solutions of various concentrations were repeatedly instilled into the eyes of normal male Sprague-Dawley (SD) rats (Japan SLC, Inc.) and SD rats whose main lacrimal glands had been removed for one week, 4 times a day, at a dosage of 5 μL / eye. Four weeks after the start of eye drops, PBS or digotinib solutions of various concentrations were instilled into the eyes at a dosage of 5 μL / eye, and anesthesia was introduced using sodium pentobarbital (Kyoritsu Seiyaku Corporation) 10 minutes later. Further, after 5 minutes, a Schirmer test paper was inserted into the conjunctival sac on the outer corner of the eye. After 1 minute, the test paper was pulled out, and the length of the wetted part of the test paper was measured, and the measured value was set as the tear volume. The results are shown in Figure 4 .

[0092] like Figure 4 As shown, the tear volume was significantly increased in the digotinib solution groups at each concentration compared with the PBS group (Steel test).

[0093] [Test Example 5: Improvement of corneal and conjunctival epithelial disease by repeated eye drops of digotinib using lacrimal gland enucleated rats]

[0094] The corneal epithelial disease-modifying effect of digotinib was evaluated using lacrimal gland-removed rats, which can be used as a dry eye model.

[0095] Fluorescein sodium (Sigma-Aldrich Japan) was dissolved in Otsuka Normal Saline (Otsuka Pharmaceutical Factory, Inc.) to prepare a 10 mg / mL fluorescein staining solution.

[0096] Digotinib was dissolved in PBS (Kohjin-Bio Co., Ltd.) and stirred to prepare digotinib solutions of various concentrations (0.0125%, 0.05%, and 0.2%).

[0097] PBS or digotinib solution of various concentrations was repeatedly instilled into the eyes of male SD rats (Japan SLC, Inc.) at a dose of 5 μL / eye, 4 times a day, after removal of the main lacrimal gland for one week. Four weeks after the start of eye drops, 10 mg / mL of fluorescein staining solution was instilled into the eyes at a dose of 1 μL / eye. After anesthesia was introduced using isoflurane inhalation anesthetic solution (Pfizer Inc.), photographs were taken using a fluorescence microscope (Leica Microsystems). The cornea photographed in the photograph was divided into four parts, and the staining score of each part was scored from 0 to 5 points. The total value of the four scores was used as the corneal epithelial disease score of the eye. The results are shown in Figure 5 .

[0098] like Figure 5 As shown, the corneal epithelial disease score was significantly reduced in the digotinib solution groups at each concentration compared with the PBS group (Steel test).

Claims

1. An ophthalmic composition for promoting tear secretion, comprising 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropionitrile or a salt thereof.

2. The ophthalmic composition according to claim 1, which is used for improving corneal and conjunctival epithelial diseases. The ophthalmic composition according to claim 1 , which is used for improving dry eye syndrome.

4. An ophthalmic composition for improving corneal epithelial diseases, comprising 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropionitrile or a salt thereof.

5. The ophthalmic composition according to claim 2 or 4, wherein Corneal and conjunctival epithelial diseases result from dry eye syndrome.

6. The ophthalmic composition according to any one of claims 1 to 5, wherein The content of 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropionitrile or its salt is 0.01% by mass to 1% by mass based on the total amount of the ophthalmic composition. 7 . The ophthalmic composition according to claim 1 , which is an eye drop.